• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.

作者信息

Konstantinou Maria P, Tournier Emilie

机构信息

Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France.

Pathology Department, University Institute of Cancer Toulouse Oncopole and University Hospital of Toulouse, Toulouse, France.

出版信息

Int J Dermatol. 2022 Nov;61(11):1409-1411. doi: 10.1111/ijd.16269. Epub 2022 May 15.

DOI:10.1111/ijd.16269
PMID:35569068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9790644/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eb8/9790644/3c1a1a85f720/IJD-61-1409-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eb8/9790644/afe09968d07d/IJD-61-1409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eb8/9790644/3c1a1a85f720/IJD-61-1409-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eb8/9790644/afe09968d07d/IJD-61-1409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5eb8/9790644/3c1a1a85f720/IJD-61-1409-g002.jpg

相似文献

1
Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.携带RET和MAP2K1突变的皮肤型罗萨伊-多夫曼病，经甲氨蝶呤治疗成功。
Int J Dermatol. 2022 Nov;61(11):1409-1411. doi: 10.1111/ijd.16269. Epub 2022 May 15.
2
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.罗道尔夫病中相互排斥的 KRAS 和 MAP2K1 突变。
Mod Pathol. 2017 Oct;30(10):1367-1377. doi: 10.1038/modpathol.2017.55. Epub 2017 Jun 30.
3
Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.罗萨伊-多夫曼病是一种反应性过程吗？一例罗萨伊-多夫曼病中MAP2K1 L115V突变的检测。
Virchows Arch. 2017 Oct;471(4):545-547. doi: 10.1007/s00428-017-2173-4. Epub 2017 Jun 9.
4
Pediatric recurrent Rosai-Dorfman disease with germline heterozygous SLC29A3 and somatic MAP2K1 mutations.伴有种系杂合性SLC29A3和体细胞MAP2K1突变的小儿复发性罗萨伊-多夫曼病
Ann Hematol. 2020 Dec;99(12):2965-2967. doi: 10.1007/s00277-020-04264-3. Epub 2020 Sep 17.
5
Trametinib for a child with refractory Rosai-Dorfman-Destombes disease harboring a novel somatic mutation in MAP2K1.曲美替尼治疗 MAP2K1 基因新型体细胞突变致耐药性罗道病-道斯综合征 1 例
Int J Hematol. 2024 Oct;120(4):520-524. doi: 10.1007/s12185-024-03818-9. Epub 2024 Jul 14.
6
Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case.皮肤型罗萨伊-多夫曼病：1990年以来医学文献报道病例的综合回顾及1例典型病例展示
J Cutan Med Surg. 2006 Nov-Dec;10(6):281-90. doi: 10.2310/7750.2006.00067.
7
MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.MAP2K1 驱动的朗格汉斯细胞组织细胞增生症、罗道尔夫-多布姆病和埃勒-当斯伯格病与急性髓系白血病克隆相关。
J Cutan Pathol. 2021 May;48(5):637-643. doi: 10.1111/cup.13918. Epub 2020 Nov 24.
8
Cutaneous Rosai-Dorfman disease successfully treated with low-dose methotrexate.低剂量甲氨蝶呤成功治疗皮肤型罗萨伊-多夫曼病。
JAMA Dermatol. 2014 Jul;150(7):787-8. doi: 10.1001/jamadermatol.2013.8679.
9
Low-dose weekly methotrexate used to treat cutaneous Rosai-Dorfman disease.低剂量每周一次甲氨蝶呤用于治疗皮肤型罗萨伊-多夫曼病。
Clin Exp Dermatol. 2018 Oct;43(7):849-851. doi: 10.1111/ced.13665. Epub 2018 Jun 4.
10
Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide.位于乳房的皮肤型罗萨伊-多夫曼病：局部用皮质类固醇、阿维A和沙利度胺治疗失败后甲氨蝶呤的快速疗效
Acta Derm Venereol. 2015 Jul;95(6):758-9. doi: 10.2340/00015555-2057.

引用本文的文献

1
Cutaneous Rosai-Dorfman Disease: A Report of 2 Cases and a Review of Recent Literature (2018-2023).皮肤型罗萨伊-多夫曼病：2例报告及近期文献综述（2018 - 2023年）
Case Rep Dermatol. 2025 Jun 23;17(1):204-223. doi: 10.1159/000546382. eCollection 2025 Jan-Dec.
2
Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.组织细胞增多症中的分子突变：基因改变的全面综述
Mol Biotechnol. 2025 Feb;67(2):438-455. doi: 10.1007/s12033-024-01072-2. Epub 2024 Feb 20.
3
Treatment-refractory cutaneous Rosai-Dorfman disease responsive to oral methotrexate and topical trametinib.

本文引用的文献

1
RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer.RET 受体酪氨酸激酶：在神经退行性变、肥胖和癌症中的作用。
Int J Mol Sci. 2020 Sep 26;21(19):7108. doi: 10.3390/ijms21197108.
2
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.在组织细胞肿瘤中 CSF1R 和其他受体酪氨酸激酶的激活突变。
Nat Med. 2019 Dec;25(12):1839-1842. doi: 10.1038/s41591-019-0653-6. Epub 2019 Nov 25.
3
Efficacy of MEK inhibition in patients with histiocytic neoplasms.MEK 抑制在组织细胞肿瘤患者中的疗效。
对口服甲氨蝶呤和外用曲美替尼有反应的难治性皮肤罗萨伊-多夫曼病
JAAD Case Rep. 2023 Jul 7;39:74-77. doi: 10.1016/j.jdcr.2023.06.038. eCollection 2023 Sep.
Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.
4
Low-dose weekly methotrexate used to treat cutaneous Rosai-Dorfman disease.低剂量每周一次甲氨蝶呤用于治疗皮肤型罗萨伊-多夫曼病。
Clin Exp Dermatol. 2018 Oct;43(7):849-851. doi: 10.1111/ced.13665. Epub 2018 Jun 4.
5
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.罗道尔夫病中相互排斥的 KRAS 和 MAP2K1 突变。
Mod Pathol. 2017 Oct;30(10):1367-1377. doi: 10.1038/modpathol.2017.55. Epub 2017 Jun 30.
6
Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate.通过抑制羧基甲基化靶向Ras信号传导：甲氨蝶呤的意外特性。
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6529-34. doi: 10.1073/pnas.1135239100. Epub 2003 May 15.
7
Cutaneous rosai-dorfman disease is a distinct clinical entity.皮肤型罗萨伊-多夫曼病是一种独特的临床实体。
Am J Dermatopathol. 2002 Oct;24(5):385-91. doi: 10.1097/00000372-200210000-00001.